HY PHAN: Open Payments
NPI 1144373408 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$678 in 27 payments from 10 companies in 2025. Trend: 2023 $1,126 · 2024 $1,099 · 2025 $678
Food & beverage: $600Education: $78
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 5 | $152 |
| Otsuka America Pharmaceutical, Inc. | 6 | $135 |
| Teva Pharmaceuticals USA, Inc. | 2 | $97 |
| E.R. Squibb & Sons, L.L.C. | 4 | $83 |
| Janssen Pharmaceuticals, Inc | 3 | $53 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $50 |
| Alkermes, Inc. | 2 | $42 |
| ABBVIE INC. | 1 | $26 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $18 |
Products named: INGREZZA, REXULTI, COBENFY, INVEGA SUSTENNA, CAPLYTA, ARISTADA, VRAYLAR, Auvelity.
Industry payments across CA — which companies pay providers there.
